Are you planning to attend World ADC Asia 2025 in Incheon, South Korea, between June 10-12, 2025?

If so, make sure to connect with Abzena at the event. Our bioconjugate and ADC experts will be on hand to discuss all your discovery, development and manufacturing needs.

Event Details:

Dates: June 10-12
Location: Incheon, South Korea
Event website: World ADC Asia 2025

There is significant diversity in the design of an ADCs, including the antibody, linkers, conjugation chemistries and drug, which makes the process for scaling up even more complex. Being aware of the challenges from the outset can help to mitigate risk when it comes time to scale-up and manufacture an antibody-drug conjugate.

From understanding the functionalization of the antibody, to the conjugation reaction and downstream purification and formulation, all these stages play a critical part in ensuring the downstream success and delivery of your ADC. Abzena understand the challenges and can help you overcome even the most complex projects.

Discover ThioBridge™ and overcome your ADC design and delivery challenges with our platform technology. ThioBridge™ offers is a solution that provides a more uniform DAR profile, stable linker attachment, and improved pharmacokinetic properties. Do not miss your chance to meet and connect with our ADC experts about ThioBridge™, at the premier ADC forum to leverage our unparalleled knowledge across cutting-edge R&D, end-to-end development strategy, and global market insights.

Complete the form below to schedule a meeting and learn how Abzena’s integrated solutions can help accelerate your biologic drug development journey.

About Abzena

Abzena is the leading end-to-end bioconjugate, ADC and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. We have research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.